A research team at the Medical University of Vienna led by Maria Sibilia has investigated a new combination therapy against cancer.

In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.